Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Arcutis Biotherapeutics Expects Continued Reductions In R&D Expenses In 2024 As It Focuses Investments In Ongoing Commercial Launches For Zoryve (Roflumilast) Topical Foam For Seborrheic Dermatitis

Author: Benzinga Newsdesk | February 27, 2024 06:54am

Posted In: ARQT